Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Acalabrutinib
Related studies linked through entity extraction aliases.
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
- Status
- RECRUITING
- Phase
- PHASE2
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
- Status
- COMPLETED
- Phase
- PHASE2
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
- Status
- TERMINATED
- Phase
- PHASE2
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2